| Abstrakt: |
A recent report from the Chinese Academy of Medical Sciences in Beijing, People's Republic of China, discusses the design and synthesis of a novel PSMA-PI3K small molecule drug conjugate for targeted cancer therapy. The conjugate demonstrated potent inhibition against PI3K and selectively inhibited the growth of PSMA-positive cancer cells. In vivo evaluation showed favorable efficacy and tolerability in a xenograft model, suggesting potential application in targeted cancer therapy. Financial support for this research came from the CAMS Innovation Fund for Medical Sciences. [Extracted from the article] |
